20.6 C
New York
Thursday, June 18, 2026

Tag: third quarter

newssourceFORcompanyinformationcontent1marketreleases

Alkami Announces Second Quarter 2025 Financial Results

PLANO, Texas, July 30, 2025 /PRNewswire/ -- Alkami Technology, Inc. (Nasdaq: ALKT) ("Alkami" or "the Company"), a leading cloud-based digital banking solutions provider for...

eBay Inc. Reports Second Quarter 2025 Results

Revenue of $2.7 billion, up 6% on an as-reported basis and up 4% on an FX-Neutral basisGross Merchandise Volume ("GMV") of $19.5 billion, up...

Equinix Reports Second-Quarter 2025 Results

REDWOOD CITY, Calif., July 30, 2025 /PRNewswire/ -- Deepened customer engagement, with 4,100 deals closed across more than 3,300 customers and $345 million in annualized...

CPKC second quarter delivers strong growth, carries momentum into second half of 2025

CALGARY, AB, July 30, 2025 /CNW/ - Canadian Pacific Kansas City (TSX: CP) (NYSE: CP) (CPKC) today announced its second-quarter results, including revenues of $3.7...

Synopsys Announces Earnings Release Date for Third Quarter Fiscal Year 2025

SUNNYVALE, Calif., July 30, 2025 /PRNewswire/ -- Synopsys, Inc. (Nasdaq: SNPS) today announced it will report results for the third quarter fiscal year 2025...

Spineway : H1 2025 results – Continued improvement in results and financial position

Press release        

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer’s Association International Conference (AAIC) 2025

TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.

Q3 TRADING UPDATE FOR THE THREE MONTHS ENDED 30 JUNE 2025: HBX GROUP

LONDON, July 30, 2025 /PRNewswire/ -- HBX Group (HBX.SM), a leading independent B2B travel technology company, today issues a Q3 trading update for the three...

CHAMPION IRON REPORTS ITS FY2026 FIRST QUARTER RESULTS, AND ADVANCES THE DRPF PROJECT AS SCHEDULED

Quarterly production of 3.5M wmt, record level of sales of 3.8M dmt, revenue of $390M, EBITDA of $58M1 and EPS of $0.05Reduced inventories of...

TETRA TECHNOLOGIES, INC. ANNOUNCES STRONG SECOND QUARTER 2025 RESULTS AND PROVIDES FULL YEAR GUIDANCE

Second Quarter 2025 Financial Highlights Revenue of $174 million increased 11% sequentiallyNet income before taxes of $19.4 million increased $14.4 million sequentiallyAdjusted EBITDA of $35.9...

Sound Financial Bancorp, Inc. Q2 2025 Results

SEATTLE, July 29, 2025 (GLOBE NEWSWIRE) -- Sound Financial Bancorp, Inc. (the "Company") (Nasdaq: SFBC), the holding company for Sound Community Bank (the "Bank"), today reported net income of $2.1 million for the quarter ended June 30, 2025, or $0.79 diluted earnings per share, as compared to net income of $1.2 million, or $0.45 diluted earnings per share, for the quarter ended March 31, 2025, and $795 thousand, or $0.31 diluted earnings per share, for the quarter ended June 30, 2024. The Company also announced today that its Board of Directors declared a cash dividend on the Company's common stock of $0.19 per share, payable on August 25, 2025 to stockholders of record as of the close of business on August 11, 2025.  

CubeSmart Declares Third Quarter 2025 Dividend

MALVERN, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- CubeSmart (NYSE: CUBE) announced today that its Board of Trustees declared a quarterly dividend of $0.52 per common share for the period ending September 30, 2025. The dividend is payable on October 15, 2025 to common shareholders of record on October 1, 2025.  

American Assets Trust, Inc. Reports Second Quarter 2025 Financial Results

Net income available to common stockholders of $5.5 million and $48.0 million for the three and six months ended June 30, 2025, respectively, or $0.09 and $0.79 per diluted share, respectively.

Purple Innovation Reports Second Quarter 2025 Results; Reaffirms 2025 Guidance

Net Loss Exceeded Expectations; Adjusted EBITDA Margin Improved 120 Basis Points versus Last Year Strong Rejuvenate 2.0 Demand More than Double the Rejuvenate 1.0 Launch...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsThird quarter

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers